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ABSTRACT 
 
Background 
 
The World Health Organisation currently recommends the use of artemisinin-based 
combination drugs for treatment of uncomplicated malaria in high malaria endemic 
regions. However, comprehensive understanding of factors affecting treatment of malaria 
with antimalarials is lacking in many rural communities in Africa. This study seeks to test 
the following hypothesise: 
1. That socio-economic and demographic factors at the household level affect treatment 
of self reported malaria/fever with antimalarials in the Kilombero/Ulanga and Rufiji 
valleys in Tanzania 
2.  Distance of a household to a health facility affects treatment of malaria/fever with 
antimalarials in the Kilombero/Ulanga and Rufiji valleys in Tanzania. 
Methods: Secondary data analysis of a cross- sectional household survey on antimalarials 
carried out in 2005 in the Kilombero/Ulanga and Rufiji valleys in Tanzania. Geo-
referenced health facilities and households’ datasets from the Rufiji and Ifakara 
demographic surveillance systems sites were also used to estimate distance variables.  
 
Results: Out of a total of 1433 participants who reported malaria/fever, 32% (95% CI: 
29.29, 34.89) obtained treatment with antimalarials. Among them, 36% obtained treatment 
with Sulfadoxine Pyreminthamine (SP) as a monotherapy and 44% treated malaria/fever 
with SP and Artesunate as a combination therapy.8% used quinine while 11 % used 
Amodiaquine and Artesunate. The remaining 1% used chloroquine. After adjusting for all 
confounding variables in a multivariate survey logistic regression model, age group, 
education level of the household head and district of residence were found, with statistical 
evidence, to be associated with treatment of reported malaria/fever with antimalarials. 
 v 
 
 
Conclusion:  
The results suggest that participant’s age, education level of household head and location 
of district are important predictors of treatment of malaria with antimalarials in rural 
Tanzania. The implementation of any antimalarials policy in Tanzania would therefore, 
require a careful consideration of these factors. 
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Definition of Key Terms 
Anti-malaria drug resistance:  the ability of the malaria parasite strain to                                                   
 survive and/or multiply despite the administration and absorption of a drug given in doses 
equal to or higher than those usually recommended, but within the limits of tolerance of the 
subject. (The use of antimalarial drugs. A WHO report of an informal consultation, Geneva 
200033).                                                                                                                                                            
Antimalarial: A drug that can be used to treat or prevent malaria. 
Artemisinin-based combination therapy: Treatment of uncomplicated malaria that 
combines several antimalarial drugs, one of which is a derivative of artemisinin. (Francis 
Nosten, FAQs on Artemisinin based Combination Therapy). 
Monotherapy: The use of a single antimalarial to treat or prevent malaria (The use of 
antimalarial drugs. A WHO report of an informal consultation, Geneva, 2000). 
1km block, 5km block and 10km block: Study participants whose households fall within 
1 kilometre, 5 kilometres or 10 kilometres from the nearest health facility. 
Facility was defined as health centre, clinic or any drug shop, licensed or unlicensed, 
selling either antimalarials or any type of drug. 
Geo-referenced health facilities and households: Facilities and households that can be 
described by latitudes and longitudes i.e. the latitudes and longitudes passing through these 
structures are known.  
Wealth quintiles: Using wealth index based on ownerships of household and 
characteristics of housing materials to categorize study participants into five socio-
economic status groups; most poor, very poor, poor, less poor, and least poor. 
Multinomial model: A statistical model that examines several risk factors to a single 
outcome variable. 
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Parsimonious model: A statistical model that is simple and can satisfactorily explain the 
relationship between the independent variable and the explanatory variables. 
“Abiku”: Children from the spirit world. 
KVIP: Kumasi Ventilation Improved Pit- A type of toilet facility (INDEPTH Monograph 
on causes of death). 
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ABREVATIONS AND ACRONYMS 
 
 
DSS :                        Demographic Surveillance System 
 
 
ACT :                       Artemisinin -based Combination therapy. 
 
 
WHO :                     World Health Organisation 
 
 
SP  :                        Sulfadoxine Pyreminthamine 
 
INDEPTH:             International Network for Continuous Demographic Evaluation of 
                           Populations and their impact on Health in Developing Countries 
 
IMPACT :           Interdisciplinary Monitoring Project on Artemisinin based 
                           Combination Therapy. 
 
SQL :                  Structured Query Language. 
KVIP:                Kumasi Ventilation Improved Pit (INDEPTH monograph)  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background   
 
Malaria remains a leading global public health problem. Despite efforts by public health 
systems of malaria endemic countries to control the disease the World Health Organisation 
(WHO) annual malaria reports have, over the years, consistently presented unacceptable 
high levels of malaria morbidity and mortality in malaria endemic countries. An estimated 
3.2 billion people; representing about 50% of the world population are at risk of malaria 
infection.1  Between 350 and 500 million people are infected with malaria annually 
resulting in annual mortality of between 1.5 and 2.7 million worldwide1. Children and 
pregnant women are more at risk of malaria infection and mortality1.  
 
About 60% of all clinical cases and 80% of all deaths due to malaria occur in African 
countries, south of the Sahara.1. To change this situation, African countries pledged at a 
meeting in Abuja in 2000, to ensure that, at least: 1) 60% of those suffering from malaria, 
have prompt access to, and are able to correctly use, affordable and appropriate treatment 
within 24 hours of the onset of symptoms, 2) 60% of those at risk of malaria, particularly 
children under five years of age and pregnant women, benefit from the most suitable 
combination of personnel and community protective measures such as insecticide treated 
mosquito nets and other interventions which are accessible and affordable to prevent 
infection and suffering and 3) 60% of all pregnant women who are at risk of malaria, 
especially those in their first pregnancies, have access to  chemoprophylaxis or 
presumptive intermittent treatment  20052. 
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Tanzania is malaria endemic country and transmission of the disease in the country varies 
regionally with the pattern of seasonal factors such as rainfall. About 28 million people in 
Tanzania (80% of total population) are at risk of malaria infection.16 million episodes of 
malaria cases are recorded annually in Tanzania3. Malaria is the main cause of health 
services attendance in Tanzania. It is reported that 38%of children and 32% of adults seen 
at the out patient departments of hospitals in Tanzania are diagnosed with malaria. Malaria 
is also the single largest cause of child morbidity and mortality in Tanzania. About 100, 
000 children die annually of malaria in Tanzania, representing 25% of all deaths3 . 
 
The negative economic impact of malaria on Tanzania is enormous. One percent, (1%) of 
Tanzania’s GDP and 39% of its total health expenditure is spent on fighting malaria4 . 
According to the annual cause of death of both the Ifakara and Rufiji demographic 
surveillance sites, malaria is the leading cause of infant morbidity and mortality in the 
respective coverage areas of the surveillance sites.5  
 
Malaria mostly affects the economically marginalised, poorly educated and those who lack 
access to quality health care6. The resistance of the malaria parasite, especially, 
plasmodium falciparum, against chloroquine has not help the course of the poor to fight the 
disease. Chloroquine is widely available and comparatively cheaper. Therefore, the 
increasing ineffectiveness of chloroquine against malaria is severely limiting efforts to 
fight the disease6 
 
 To address the growing malaria drug resistance problem the World Health Organisation 
recommends artemisinin- based combination therapy, ACT1. The recommendation is based 
on a valid scientific reason that if two drugs, with independent working mechanisms, are 
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used in combination for treatment of the disease, the probability of the malaria parasite 
developing resistance against the two drugs simultaneously is very small7. Artemisinin -
based combination therapy, ACT, has been recommended to be the most promising 
alternative for the treatment of malaria in areas where the malaria parasite has become 
resistant against monotherapies such as chloroquine and Sulfadoxine Pyreminthamine 
(SP)8.But the question is whether drug efficacy alone is sufficient to control the resurging 
incidence of malaria morbidity and mortality in Africa. Drug efficacy is necessary but not 
sufficient for tackling the growing malaria problem6. The socio-cultural, economic, 
technical and political environment need to be considered in tackling this problem 6. 
 
Thus, to ensure successful up-scaling of artemisinin -based combination therapy, factors 
that may possibly affect uptake of the recommended antimalarials will have to be fully 
explored and understood so as to inform policy formulation and implementation of the 
WHO recommended combination therapy programme. 
 
1.2 STATEMENT OF THE PROBLEM 
There is paucity of information on the prevalence of use of antimalarials for treatment of 
malaria in rural communities that could inform effective malaria drug policy such as up-
scaling of combination therapy. Also factors that influence treatment of the disease in poor 
and remote areas in many parts of Africa are diverse and poorly understood, especially at 
the household level. Lack of vital information relating to treatment of malaria in rural 
populations will impede successful implementation of the recommended combination 
therapy currently being considered by malaria endemic countries including Tanzania.  
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1.2 JUSTIFICATION 
One of the most effective ways of improving the quality of treatment of malaria in rural 
communities is by monitoring the use of anti-malaria drugs. Monitoring the use of 
antimalarials prevents drugs resistance which will eventually improve the efficacy of the 
recommended antimalarials. 
 
 This study will explore factors that explain the difference between people who 
experienced episodes of malaria/fever in the Kilombero/Ulanga and Rufiji valleys in 
Tanzania in 2005, and sought treatment with any antimalarial and those who experienced 
malaria/fever but did not seek treatment with antimalarials. This information will be key to 
a successful up-scaling of the WHO recommended artemisinin- based combination therapy 
in Tanzania and many African countries planning to implement this policy.  
 
 Further discussions could also be generated from the findings of this study that will be 
useful, not only to the government of Tanzania, but other malaria endemic countries in 
Africa for implementation of artemisinin- based combination therapy. To improve 
coverage and quality of treatment against malaria it is also relevant to know the prevalence 
of treatment for the disease. This will be useful for any drug policy planning. Also 
information on the pattern of consumption of antimalarials across age groups will throw 
light into the segment of the population in most need of attention. 
 
1.3 LITERATURE REVEW 
Global strategy for malaria control focuses on case management through early detection 
and effective treatment of all malaria cases9. As part of the integrated management of 
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childhood illness, the World Health Organization advocates presumptive treatment of 
malaria in febrile children less than five years in intense malaria transmissions areas10. 
Surveys in many African countries have revealed that half African children who 
experienced fever are treated with an antimalarial, mostly chloroquine.10 Studies in 
Madagascar and Tanzania on providing prompt access to antimalarials for treatment of 
malaria demonstrated significant reduction in malaria related mortality.10  
 
 Until recently chloroquine was the most effective and widely used first line antimalarial 
for the treatment of uncomplicated malaria in malaria endemic countries10. It was also 
affordable to the poor, the segment of the population who bear the brunt of the malaria 
pandemic1. By the year 2000, chloroquine resistance had been widely reported in many 
malaria endemic countries in Africa11. Chloroquine resistance is responsible for increased 
morbidity and mortality attributable to malaria in sub-Saharan Africa in the past decade6. 
Two to three fold increase in malaria morbidity and mortality has been attributed to 
chloroquine resistance. Significant rise in malaria mortality in children under five years 
coinciding with chloroquine resistance has been observed in Senegal, West Africa11 . 
 
As a result of the declining effectiveness of chloroquine against malaria, it has been 
replaced as a first line drug for the treatment of uncomplicated malaria in almost all 
malaria endemic countries in Africa11. In 1993, Malawi replaced chloroquine with 
Sulfadoxine Pyreminthamine as a first line drug for the treatment of uncomplicated 
malaria11.Chloroquine resistant Plasmodium falciparum malaria had been recognised in 
united republic of Tanzania since the early 1990s12. Monitoring studies in the 1990s 
showed that most malaria related deaths (48%-88%) occur in homes even though more 
than 80% of Tanzanians live close to drugs shops that sell chloroquine.12  
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Tanzania changed its malaria treatment policy from Chloroquine to Sulfadoxine 
Pyreminthamine in the year, 2000 after it was established that chloroquine was no longer 
effective against uncomplicated malaria11. Kenya and South Africa also modified their 
malaria treatment policies and has introduced Sulfadoxine Pyreminthamine, SP, as a first 
line drug for treatment of uncomplicated malaria11. However, resistance of the malaria 
parasite, mostly Plasmodium falciparum, against SP has also been reported in the eastern 
and southern parts of Africa including Tanzania13. Quinine is recommended for the 
treatment of severe malaria. However, the WHO recommends the use of parenteral 
artemeter/artesunate for the treatment of severe malaria in areas where the malaria parasite, 
plasmodium falciparum, resistance or sensitivity to quinine is not known 9. 
 
 Because of the increasing resistance of the malaria parasite against monotherapy, the 
WHO current policy on malaria treatment is combination therapy; the use of two or more 
antimalarials with, at least one of them, containing a derivative of artemisinin7. The WHO 
further recommends that the two antimalarials should also have independent working 
mechanisms. This will be necessary to fight resistant malaria parasites as the different 
pharmacodynamic properties of the drugs is able to deal with the various elusive 
mechanisms of the malaria parasite7. The aim of this recommendation is to improve 
efficacy and retard the development of resistance of the malaria parasite against 
components of the combination drugs8.Artemisinin-based Combination Therapy is now 
generally considered to be the best option for the treatment of uncomplicated malaria in 
endemic areas14 . 
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However, the WHO initiative to fight malaria using combination therapy could be thwarted 
by retail trade   in monotherapies in rural communities. 
 
 In a survey in Dar-Es-Salaam, nineteen different Artemisinin-containing oral 
Pharmaceutical products, including one co-formulated product, one co-packaged product, 
and 17 monotherapies were found to be displayed in chemical shops with inconsistent 
dosing instructions and inadequate internationally recommended dosage15.It was also 
established that none of the monotherapies mentioned the potential benefits of combining 
one drug with other antimalarials for treatment of malaria. Thus, despite the call by the 
WHO for the voluntary withdrawal of these monotherapies from the market these drugs are 
likely to coexist with the recommended combination therapies15. 
 
 Many factors affect the use of antimalarials for treatment against malaria. Accessibility 
and affordability play significant part in accessing antimalarials especially in rural 
populations16. Rural populations may resort to inexpensive but less effective antimalarials 
for treatment against malaria. Chloroquine, Sulfadoxine Pyreminthamine and Amodiaquine 
cost about US $0.13, US$0.14 and US$ 0.20 respectively per dose. However, artemisinin 
based- combination drugs cost between US$1 and US$3 2. The total cost of treating an 
episode of malaria could even reach 8.67 dollars if one adds the indirect cost of travelling 
to a health centre and the time spent waiting to receive service17. Thus, Even though 
combination therapy looks promising to fight drug resistant malaria the cost of these drugs 
will be an obstacle to acceptance and effective utilization of combination therapy by the 
poor who are mostly affected by the disease. This may adversely affect up-scaling of the 
WHO new treatment policy on malaria.  
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Low malaria treatment has been identified to be associated with low socioeconomic status 
in Ifakara, a rural community in Tanzania18 while a study in Malawi identified access to 
media, place of residence and care givers age to be associated with treatment of self-
reported malaria/fever19. 
 
National surveys in twenty eight African countries in Africa indicated an average of 42% 
of children less than fives with fever were treated; more than 80% of the treatment 
involved the use of chloroquine20. It is even possible effective treatment in the surveyed 
communities could even be lower as low level of education could make dosing instructions 
difficult to follow.  
 
Other surveys in 21 African countries revealed that those who treated febrile illness with 
antimalarials, 46% obtained treatment at a health facility, 44% at home and 10% at both 
home and health facility20.Treatment of self diagnosed fever has also been found to be low 
in many Africa countries. A community based household survey in central Ethiopia 
revealed that 33% of people with self-diagnosed malaria sought treatment from community 
based health facility workers, 23% attended public health facility and 17% sought help 
from private clinic.20 Another household survey in Togo on treatment received by febrile 
children showed that, 20% (95% CI: 15%-25%) had sought treatment from a health 
facility, while 83% (95% CI: 76%-90%) were treated at home with antimalarials. Among 
them, 94% of those who treated at home used chloroquine.21 Coupled with this undesirable 
coverage of treatment for the disease is the lack of compliance to dosing instructions by 
care-givers of children who are affected by the disease22. 
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Other factors that affect quality treatment of malaria include indiscriminate and 
inappropriate use of drugs. Dysfunctional health systems and poor quality of antimalarials 
have also been identified to affect the quality of treatment of malaria6 
 
In the midst of what has been revealed to affect treatment of malaria with antimalarials in 
rural populations, it is not extensively understood how the socio-economic conditions of 
households, the relative distance of households to the nearest health facilities, the personal 
demographics of people such as age, sex and education level affect access to antimalarials 
for treatment of malaria with antimalarials. Therefore, before up-scaling of the WHO new 
treatment policy on malaria-combination therapy, especially in rural populations, it is 
relevant to explore how these factors may affect treatment of self reported malaria/fever 
with antimalarials. 
1.4. Study Question:  
1) What factors predict the use of antimalarials for treatment of malaria in the 
Kilombero/Ulanga and Rufiji valleys in Tanzania? 
 
Hypothesises    
1. Socio-economic and demographic factors affect treatment of malaria with anti-malaria 
drugs in the Kilombero/Ulanga and Rufiji valleys in Tanzania 
2. Distance of a household from a health facility affects treatment of malaria with     
antimalarials in the Kilombero/Ulanga valleys in Tanzania. 
 
 
 
 
 10 
 
 
1.5 Aim:  
The general aim of this study is to determine factors that predict the use of antimalarials for 
treatment of malaria in the Kilombero/Ulanga and Rufiji valleys in Tanzania. 
 
1.6 Specific Objectives.                                                                                          
1. To estimate the prevalence of anti-malarials use for the treatment of malaria in 
the Kilombero/Ulanga and Rufiji valleys.   
2. To determine the pattern of antimalarials use for treatment of malaria across age 
groups.  
3. To assess factors predicting the use of antimalarials in the Kilombero/Ulanga 
and Rufiji valleys in Tanzania for treatment against malaria. 
.                 
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CHAPTER 2 
METHODOLOGY 
 
2.1 Demographic characteristic of the study area   
 The study covered three administrative districts in rural Tanzania. The Kilombero and 
Ulanga districts in the Morogoro region and Rufiji district in the coast region. (Appendix 
1). The communities of the Kilombero and Ulanga districts are mostly subsistence farmers 
residing in the valley of the Udzungwa chain of mountains. Parts of these areas are covered 
by the Ifakara demographic surveillance system. The Ifakara demographic surveillance 
system, which was established in 1996, covers twenty five villages (25) in the two districts. 
The system monitors longitudinal demographic characteristic of about 80,000 (2004 
census) people across the two districts. Data on migration, (in-and-out), births, deaths and 
changes in marital status are collected and updated every four months in a year. Socio-
economic status or household assets data is collected once annually. All health facilities 
and drug shops in the two districts are geo-referenced. Households of all residents in the 
two districts are also geo-referenced.  
 
The Rufiji district is one of six districts in the coast region of Tanzania. It has a population 
of about 182,000 of which 47% (85,000/182,000) is under the Rufiji demographic 
surveillance system. The system covers 31 villages and monitors the same demographic 
information as the Ifakara demographic system. Health facilities, drug shops and 
households are also geo-referenced in this district. 
 
The district is rural and the people are mostly subsistence farmers. A prominent feature in 
the district is the Rufiji River which divides the district into roughly two halves. The three 
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districts were selected based on their peculiar nature of representing a rural population 
setting with intense and perennial malaria transmission. The fact that the areas are severed 
by demographic surveillance systems makes it possible and convenient to use the 
surveillance systems as sampling frames for the study to ensure collection of quality data. 
This study covered areas only under the demographic surveillance systems. 
 
2.2 Study population 
The study population includes all the resident population under coverage of the Rufiji and 
Ifakara demographic surveillance systems in 2005.  
 
2.3 Study design 
The study design is secondary data analysis of a cross- sectional household survey known 
as Interdisciplinary Monitoring Project on Artemisinin-based Combination Therapy 
(IMPACT) study in Tanzania that was carried out in 2005, in the Kilombero/Ulanga and 
Rufiji valleys in Tanzania to determine the level of usage of antimalarials for treatment of 
malaria at the household level. 
 
2.4 Inclusion and exclusion criteria 
The study was limited to only those who reported malaria or fever among the participants 
who took part in the antimalarials household survey in 2005. There was no restriction on 
age and sex in the selection of participants. However, participants were required to have 
agreed and consented to take part in the IMPACT household survey before being included 
in this analysis. Participants below 12 years had their parents or legal guardian consented 
on their behalf. Participants who fulfilled the above criteria and were also verified to have 
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a complete set of records with regard to the investigated variables were included in the 
final analysis of this report.  
 
The IMPACT household survey 
The Ifakara Health Research and Development Centre in Tanzania carried out a household 
survey in 2005 in the Rufiji and Kilombero/Ulanga valleys, areas under coverage of 
demographic surveillance systems, to assess antimalarials usage levels in the communities 
living in these valleys. The survey was also meant to determine the prevalence of the 
malaria parasite genes that confers resistance against Sulfadoxine Pyreminthamine, SP. 
However, analysis in this report did not include aspect of the dataset on SP genes 
resistance. 
Sample size and sampling strategy 
The sample size of the household survey study was chosen based on the level of use of 
antimalarials in the study; where level of use was conceived as the extend to which people 
in the study area used antimalarials, not only for treatment of malaria, but for other 
diseases. This was necessary for estimating the prevalence of the malaria parasite genes 
that confer resistance to the antimalarial,Sulfadoxine Pyreminthamine, SP. 
 
At the protocol development phase of the IMPACT study there was no information, either 
published or unpublished, on the level of use of anti-malarials, either in Tanzania or 
elsewhere, to use as a reference for calculating sample size. Therefore, an estimated 
convenient sample size of about 3700 households was chosen for the survey. With an 
average household size of about 5.3 persons, potential participants for the study were 
19610. However, 12831 from the 3700 selected households were available at the time of 
visit and consented to take part in the household survey. Parents or legal guardians of 
 14 
 
 
minors below 12 years answered questions on behalf of their wards. Those absent in the 
household at the time of the interview were missed for interview and therefore not 
recruited for the study. 
 
Cluster sampling strategy was used in selecting the households in the study areas. Rufiji 
district was chosen as a cluster while Kilombero and Ulanga districts were combined as 
another cluster and named Ifakara.Households were the primary sampling units. The 
probability of selection of the primary sampling units for each cluster was proportional to 
the estimated sample size of the primary study. From each cluster, households were then 
chosen using simple random selection.  
 
Data collection instruments were organised into modules: Module A was meant for 
collection of household assets and demographic characteristics of the household head. 
Module B was for collection of personal information of the study participant and then 
Module C was meant for collection of medical information including the history of malaria 
episodes based on two weeks recall period of the study participant.  
 
Participants were interviewed on whether they had experienced malaria/fever within the 
last 14 days preceding the interview. The local people call fever ‘homa’, in Kiswahili, the 
national language of Tanzania. Fever was used as a proxy for malaria. Those who reported 
‘’homa’’, were further asked whether they had treated the disease. For those who obtained 
treatment were further asked where they sort treatment. The name of the antimalarials used 
for the treatment of the disease or information on the nature of treatment sought was also 
collected from participants. Household assets were also collected during the interview. 
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The IMPACT survey also collected blood sample from the participants using filter paper 
blood spot samples for analysis on the type and content of antimalarials drugs as well as 
the prevalence of the genes that confers resistance against Sulfadoxine Pyreminthamine 
(SP). However, data analysis of this report did not include the subset data of blood sample 
testing. 
 
2.5 Data Source 
The data for this secondary data analysis study was extracted from the IMPACT household 
survey dataset. Variables limited to only those who reported malaria/fever were extracted 
and included in the analysis. Data from geo-referenced health facilities and household 
datasets of both the Ifakara and Rufiji demographic surveillance systems in Tanzania were 
also used in constructing variables that measured specified distance levels of a 
participating household to the nearest health facility. 
 
2.6 Description and Extraction of Variables 
Explanatory: Sex, Age, District location, Educational level of household head, Religion 
of household head, Tribe of household head, Bed net use, Socio-economic status, and 
Distance from a participating household to a health facility measured from 1km to 10 km. 
 
Outcome: The outcome variable is treatment of malaria/fever with antimalarials measured 
categorically as ‘yes’ or ‘no’ response.  
 
Extraction of the relevant variables from the household datasets was done in stata. 
The distance variables, specified as follows: 1km, 5km and 10km were created by 
converting the geo-referenced household and health facilities data into the above specified 
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kilometres using a written computer language in visual FoxPro. Structured Query 
Language, (SQL) was used to write the program. The criteria for choosing distance as a 
categorical variable and the specified distance levels were as follows: 
1. The programming language lacks the capacity to convert the geo-reference data 
into distance as a continuous variable, hence distance was categorised, 
2. The written program did not work well for specified distances less than 1km, 
3. The program could be varied to  achieve distance levels between ≥ 1km and < 1 
km, 
4. Finally, the following distance levels were thought off as reasonable enough to 
ensure that a greater number of the study participants were within a health facility 
of at least 10km. A total of 1002, representing 65% of the total study participants 
were within, at least, 10km from a health facility. The remaining 431 study 
participants representing 35% of the total included for analysis were living in 
households that were more than 10km from a health facility. 
 
The program works in the following steps: 
1. Calculates distance from drug shops, dispensaries and other drug outlets in the Ifakara 
and Rufiji demographic surveillance coverage areas, 
2. Generates spatial blocks for the study coverage Areas. The blocks are of various sizes 
from 1km to 10km, 
3. The spatial blocks are assigned numbers and finally 
4. The program generates list of those participants whose households fall within the 
specified distance (1km, 5km and 10km).  
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 A health facility was defined as a hospital, health centre, clinic or any drug shop, licensed   
or unlicensed, selling either antimalarials or any type of drug. Thus the variable, 1km   
represents all those whose households were within 1km from the nearest health facility as 
defined above. The distance variables of 5km and 10 km also represent all those whose 
households were within 5km and10km from any health facility respectively .The inclusion 
of shops that sell any type of drugs was to make sure that all possible sources of 
antimalarials were captured as those who reported not selling antimalarials might 
clandestinely intended to do so. 
 
Creation of wealth index for households using the Principal Component Analysis, 
(PCA) model. 
 
The Principal Component Analysis, PCA, was used to construct socio-economic indices   
based on household characteristics and ownership of assets. The indices were then used to 
categorise study participants households into five socio-economic groups or quintiles from 
the most poor to the least poor. 
 
 The following household characteristics and assets were included in the PCA model: floor 
of the household, walls of the room whether they were locally made or with modern 
material such as cement, cocking materials such as local or gas cylinders, water source: 
from a pipe or well, toilet facilities: local or KVIP, source of light: candle, lantern or 
electricity bicycle, car, motorbike, and animal possessions.   
 
The household characteristics and assets information was transferred from a data base 
format into stata via stata transfer. The model was based on the presence or absence of 
each asset or the nature of the housing materials .i.e. each asset was dummied with the 
response, 1 and 0. If participant had the asset the response was 1, otherwise it was assigned 
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0. For those with multiples of the same asset type, the “tab generate” command was 
invoked in stata to generate separate indices for each of the multiple assets as if each was a 
separate asset. For example, those who had more than one sheep, each sheep was 
reconstructed as a separate asset. The same procedure was applied to the household 
characteristics. The “pca” command was run to generate indices for all listed assets. The 
generated indices were used to categorise participants into five socio-economic groups or 
quintiles; most poor, very poor, poor, less poor, and least poor. 
 
2.7 Data management 
The three data collections instruments; modules A, B and C were transferred into stata 
using stata transfer, version 7.0 and linked together. Selection of variables and cleaning of 
the datasets were done in stata. Inconsistent observations were deleted. There were two 
individuals who had negative age values in the dataset and another participant had 1801 as 
age in the same dataset. Attempts to rectify these abnormal records were not successful. 
They were subsequently dropped from the dataset. Values entered for variables that were 
established to be unreasonably high or low were either deleted from the entire datasets or 
rectified with the support of thee data manager of the IMPACT household survey.  
 
The geo-referenced health facilities and household datasets were structured differently. 
These datasets were in Microsoft excel format. Stata transfer, version 7.0, was used to 
transfer the data into Microsoft FoxPro. Structured Query Language (SQL) was used to 
convert the geo-referenced data, into kilometres as described above. After the conversion, 
the data was transferred into stata using stata transfer, version 7.0. This dataset was then 
merged with the household survey data (modules A, B and C) information using family id 
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as unique identifier. A copy of the dataset was backed-up in a rewriteable CD, and a flash-
drive before proceeding with analysis. 
 
Sample for analysis 
   
  
12381 interviewed from 
3700 households             
(primary sample) 
 
 
  1433 self- 
reported 
fever/malaria in 
the previous 2 
weeks 
preceding 
interview 
 10948 said 
they did not 
experienced 
fever/malaria 
in the 
previous 2 
weeks 
preceding 
interview. 
     
             1407 had 
completed set of record 
.This is the sample size 
for the analysis 
  26 excluded because they 
either sought traditional 
treatment or could not 
mention type of treatment 
received 
 
  
 
 
 
   
 
 
425 obtained treatment 
with   antimalarials for 
self reported 
fever/malaria 
 
982 did not 
obtain any 
treatment for the 
reported 
fever/malaria 
 
  
     
 
 
Figure2.1. A flowchart presenting a summary of how the sample for analysis was extracted 
from the primary study for analysis 
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 2.8 ANALYSIS 
 Data analysis was done in stata (standard version 9.0, stata corp, Lakeway Drive-
USA).The data was surveyset using family-id (same as household) as the primary sampling 
unit, psu and location, ( Rufiji and Kil/Ulanga) as stratum. Sampling weights were fixed 
based on the final number of household that were included in the analysis to account for 
the effect of clustering at the household level.  Out of the 3700 households sampled, only 
820 had people who reported that they had experienced malaria in the last two weeks 
period preceding the interview. Out of this, 500 households came from Rufiji and 320 
households from Kilombero and Ulanga. Therefore, sampling weights were fixed based on 
these proportions of households .Data on each participant was inversely weighted by their 
probability of selection. 
 
The analytical strategy was to categorise participants into two groups; those who had 
reported malaria/fever and had access to any antimalarials for treatment and those who had 
reported malaria/fever but did not have access to antimalarials for treatment. The 
proportion of the sexes in each of the study groups was determined using a chi2 test to 
examine comparability of both sexes at baseline. A P-value of 0.05 or less was considered 
statistically significant result. 
 
The prevalence of access to antimalarials for treatment of self reported malaria/fever 
together with the 95% confidence intervals for column percentages were calculated for the 
different age categories. Graphical representation of the distribution of the reported 
malaria/fever for the Rufiji and Kilombero/Ulanga valleys were drawn using Microsoft 
excel, 2003. 
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2.10 Test of Association  
Before fitting survey regression modules, test of associations between the outcome variable 
and the explanatory variables were carried out on 2*2 tables at 5% confidence level to 
explore possible factors associated with use of antimalarials for treatment of malaria. 
Proportions of various age groups who used antimalarials for treatment were then 
tabulated. 
 
2.11 Univariate Logistic Regression Analysis 
Univariate svylogit models were first formulated to examine the association between  
treatment of the reported malaria/fever with antimalarials and the explanatory variables; 
Sex, age group , Educational level of the household head, Religion of the household head, 
Tribe of the household, District, insecticide mosquito net use, Socio-economic status, 1km, 
5km and 10k from  participants household to the nearest health facility. 
 
 The outcome variable, access to antimalarials for treatment of malaria is categorical and 
binary, i.e. whether respondents who reported malaria/fever treated the disease with any 
antimalarials or not. Before fitting the univariate models the outcome variable was 
regenerated as a dummy variable with 1 for a yes response and 0 for a no response. Odds 
Ratios, together with 95% confidence intervals were calculated for all the univariate 
logistic analysis. For the univariate distance models, the comparison was between 
participants who fell within the specified distances and those who were outside these 
distance categories. A P-value of 0.05 or less was considered statistically significant result. 
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2.12 Multivariate analysis 
Multivariate survey logistic regression analysis was then carried to determine factors 
associated with access to antimalarials for treatment of the reported malaria /fever, while 
adjusting for all possible confounding factors/variables. Various multivariate svylogit 
models were explored before arriving at a parsimonious one. Tests of interactions between 
sex and age group, Socio-economic status and education level of household head, age and 
education level of household head were carried. The final model was also tested using the 
“lfit” and the “link” test. Again a P-vaue of 0.05 or less was considered statistically 
significant.  
 
2.13 Ethical Approval 
Ethical approval was given for the use of the IMPACT dataset by the Ifakara Health 
Research and Development Centre Ethics committee. The IMPACT household survey 
itself was approved by the same ethics committee. The University of Witwatersrand ethics 
committee also gave approval for this study. A copy of the findings of this report will be 
presented to Ifakara Health Research and Development Centre for dissemination to 
participants of the household surveys, in accordance with research involving human 
participants and in keeping with agreement of collaboration between the Ifakara Health 
Research and Development Centre on one hand and the School of Public Health, 
University of Witwatersrand and the INDEPTH- Network on the other. 
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CHAPTER 3 
3.0 RESULTS 
3.1 Descriptive summaries  
About 11.6% (1433/12381) of the sample for the household survey reported that they had 
experienced malaria/fever in the last two weeks preceding the interview. About 1.8% 
(26/1433) out of these either obtained treatment from traditional sources or could not tell 
whether they used modern medicine (any antimalarial) for treatment. Therefore, 1,407 
individuals were included in the analysis. 41% of these were males while the remaining 
59% were females. However, a Chi2 test of association showed no statistical difference 
between the proportion of males and females in this sample, Pr |Chi2| = 0.907. The under 
fives year group formed 31% of the total sample size. The youngest participant was 23 
days old and the oldest 93 years. Those aged above 50 years constitutes 13% of the total 
sample size. Table1 presents a summary of the demographic characteristics of the study 
participants. 
 
There is low level of education among the household heads of study participants even 
though this may not reflect on the educational situation in the general population in the 
study area. Among the study sample, 31% lived in households where the head of that 
household had never been to school, while 20 % of the participants’ heads of household 
had less than seven years of primary education. However, 40% of them came from 
households where the head of the household completed primary education. But the level of 
education among household heads declined sharply to about 7% in the Ordinary-level and 
above education category i.e 7% of the study participants’ heads of household had formal 
education up to the ordinary level or beyond. 
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About 68% of the study participants came from households where the head practices Islam 
and 30% Christianity. This is quite a difference but it does not reflect on the true 
proportional representation of Islam and Christianity in the general population of Tanzania, 
as both religions are reported to be equally represented in many parts of the country though 
it may vary slightly from one area to another.(Dr.Rose Nathan, head of the Ifakara DSS: 
personal communication). 
 
About 58% of the study participants were sleeping under treated insecticide bed nets in the 
two weeks preceding the interview and up to the time of the interview. The remaining 42% 
were not using mosquito nets to protect themselves from mosquitoes and other insects’ 
bites. 
 
Table3.1: Socio-demographic characteristics of study participants. 
Variable Category No 
% representation in the 
sample 
Sex Total 1407  
 Male 576 41 
 Female 831 59 
Age 
 Total 1407  
 0-4 441 31.34 
 5-10 251 17.84 
 11-16 78 5.54 
 17-22 92 6.54 
 23-28 83 5.9 
 29-34 85 6.04 
 35-40 86 6.11 
 41-46 62 4.41 
 47-52 40 2.84 
 Over 52 189 13.43 
Education level of household head
 Total 1407  
 None 449 32 
 incomplete primary 294 21 
 complete primary 565 40 
 O-level+ 99 7 
Socio economic status 
 Total 1407  
 Most poor 226 16 
 Very poor 300 21 
 Poor 265 18 
 Less poor 315 23 
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 least poor 301 22 
Religion of household head 
 Total 1407  
 Christianity 434 30.82 
 Islam 965 68.54 
 Local/none 8 0.64 
Mosquito bed net 
use    
 Total 1407  
 Yes 816 58.03 
 No 591 41.97 
Location/District 
 Total 1407 100 
 Rufiji 860 61.08 
 Kilombero 304 21.59 
 Ulanga 243 17.33 
Tribe of household head 
 Total 1407  
 Ndama 59 4 
 Ndengereko 597 42 
 Pogoro 143 10 
  Others 608 44 
Distance to Health 
facility Total 1407  
 1km 285*  
 5km 556* Concurrent with 1km 
 10km 914 
65% are at least 10km 
from a health facility 
 >10km 493 
35% fall outside 10km 
from a health facility 
 
*Participants who fall within 10km from a health facility are also within 1 km and 5km 
from the same health facility.ie they run concurrently. 
 
 Reported malaria/fever distribution across age groups 
Out of 12381 individuals interviewed, 1433 said they had experienced malaria or fever in 
the last two weeks preceding the interview. This constitutes 11.6% (1433/12381) of the 
total number of people interviewed. Twenty six, (26) of those who reported malaria/fever 
either sought traditional treatment or could not tell whether they had used “modern 
medicine” (any antimalarial for treatment). These were not included in subsequent analysis 
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after calculating the prevalence of malaria/fever since it was not possible to tell the sort of 
treatment they received. 
 
 Prevalence of malaria/fever in the under- five years age group is 31.49%.This is the 
highest among all the age groups. Prevalence of the illness generally decreases across age 
groups, from about 18% among those between 5 and 10 years to about 3% in those aged 
between 42 and 52 years. Figure3.1 below illustrates the reported malaria/fever against age 
group. 
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Fig 3.1: Distribution of reported malaria/fever across age groups in the 
Kilombero/Ulanga and Rufiji valleys in Tanzania, 2005 
 
 
 
3.3 Prevalence and pattern of treatment across age groups. 
Out of the 1407 participants who could tell whether they had modern medicine or did not 
take any medication even though they had malaria/fever, only 425 obtained treatment with 
an antimalarial. This represents 32 % (95% CI: 29.29%- 34.89%) of the total sample. 
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Treatment seems to fluctuate across the various age groups. However, a Pearson chi2 test 
(Pr =0.0239) , of association showed treatment is statistically associated with age. 
Table 3.2 presents the proportion of each age group obtaining treatment. There are two age 
groups: 23 to 28 and 35 to 40 years that obtained more treatment than the other age groups. 
The general trend seems to suggest that treatment increases with age group. 
  
About 36 % of those obtaining treatment had done so with Sulfadoxine Pyreminthamine, 
SP, as a monotherapy and 44% treated the reported malaria with SP+ Artesunate 
combination. 8% used quinine while 11 % used Amodiaquine only .The remaining 1% 
used chloroquine. 
 
 
Table 3.2: Proportion of age group obtaining treatment for self reported malaria/fever 
 
Age 
group/yrs 
No % obtaining 
treatment 
           (% ) 
95% CI for column percentages 
Total 425/1407 32.03 29.29,  34.89 
Under fives 113/441 27.01 22.7, 31.8 
5-10 65/251 29.58 23.69, 36.24 
11-16 18/78 25.21 16.12,  37.15 
17-22 29/92 33.02 23.94, 43.57 
23-28 36/83 44.61 34.03, 55.71 
29-34 29/85 36.54 26.17, 48.32 
35-40 34/86 42.89 32.79, 53.62 
41-46 20/62 32.18 21.55, 45.06 
47-52 14/40 33.94 20.87, 50.02 
Over 52 67/189 36.46 29.68, 43.83 
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 Univariate logistic regression analysis. 
Analysis with univariate survey logistic regression models revealed that, age group, bed 
net use, education level of household head, socio-economic status, tribe of participant’s 
household head and the district of the participant are all statistically associated with 
treatment of malaria.  
 
Those aged between 23 and 28 years were 2.17 times more likely to obtain treatment than 
those below fives years of age, [unadjusted OR=2.17, P-value=0.002.(95% CI: 
1.326,3.575).The 35 to 40 years age group were 2 times more likely to obtain treatment 
than the under five year group.[unadjusted OR=2.01, P-value= 0.004, (95% 
CI:1.257,3.277),] while study participants who were aged above 52 years were 1.55 times 
more likely to obtain treatment than the under fives. [Unadjusted OR=1.55, P-value=0.026, 
(95% CI: 1.055, 2.2792)]. However, the difference between the other age groups and the 
under fives were not statistically significant on the univariate model. 
 
With regards to education, study participants whose household heads had some education 
but did not complete  primary education were 1.59 times more likely to obtain treatment 
with antimalarials than study participants whose household heads had never been to 
school, [unadjusted OR=1.59, P-value= 0.011, (95% CI: 1.110 ,2.2767)].Participants 
whose head of  household had completed primary education were 1.8 times more likely to 
seek treatment compared to those whose household heads had never been to school, 
[unadjusted OR= 1.80, P-value= 0.0001, (95% CI: 1.321,2.464)]. For those whose 
household heads had either completed Ordinary level (O-level) or above the O-level were 
2.5 times more likely to seek treatment for the reported malaria/fever than those whose 
household heads had never been to school, [unadjusted OR= 2.51, P-value=0.001, (95% 
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CI: 1.429, 4.400).However, There is no statistical evidence to support an association 
between sex and treatment of malaria. 
 
The univariate analysis also revealed that there is an association between district location 
and treatment of malaria. Participants from Kilombero and Ulanga districts were less likely 
to seek treatment compared to participants from the Rufiji district. Participants from the 
Kilombero district were 0.33 (33%) less likely to obtain treatment, [unadjusted OR, =0.33, 
P-value=0.0001, (95% CI: 0.245, 0.450)] compared to participants from the Rufiji district 
who were assigned comparison odds of 1. Participants from the Ulanga district were 0.46 
(46%) less likely to obtain treatment compared to those from the Rufiji district. [OR=0.46 
P-value=0.0001, (95% CI: 0.309, 0.700)]. 
 
Tribe was also statistically significant in the univariate analysis. For participants who 
belong to the Ndengereko tribe, they were 0.411 (41%) less likely to treat their 
malaria/fever ailment with antimalarials compared to the Ndama ethic group. [Unadjusted 
OR=0.411, P-value=0.005, (95% CI: 0.221, 0.765)]. There was no statistical evidence to 
support the differences between the other tribes and the Ndama tribe, which was used as 
the comparison tribe. The odds ratios together with 95% confidence intervals of the 
univariate models are tabulated in table 3.3 below. 
 
Socio economic status of the study participants was also found with statistical evidence, in 
the univariate analysis, to be associated with treatment of self reported malaria/fever with 
any antimalarial. The least poor were 1.7 times more likely to obtain treatment compared 
to the most poor group, [unadjusted OR= 1.7, P-value=0.021 (95% CI: 1.083, 2.636] while  
the less poor  were 1.6 times more likely to treat compared to the most poor, [unadjusted 
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OR=1.60, P-value=0.034, (95% CI:1.0376, 2.490).The difference between the poor and the 
most poor as well as between the very poor and the most poor have no statistical 
significance on the univariate model . 
 
Participants who were sleeping under insecticide treated mosquito’s bed nets were 1.71 
times more likely to obtain treatment than those who were not using insecticide treated 
mosquitoes’ bed nets.[unadjusted OR=1.71, P-value=0.001, 95% CI: 1.312, 2.220)]. 
 
Table 3.3: Odd Ratios together with 95% confidence intervals for univariate analysis 
examining the association between treatment of the reported malaria and explanatory 
variables. 
 
Variable 
OR P-value 95% CI 
Age group 
under fives 1   
5-10 1.13 0.498 0.787    1.637 
11-16 0.91 0.757 0.503    1.648 
17-22 1.33 0.263 0.806    2.200 
23-28 2.18 0.002 1.326     3.575 
29-34 1.56 0.098 0.922     2.625 
35-40 2.03 0.004 1.257     3.277 
41-46 1.28 0.402 0.716     2.297 
47-52 1.39 0.359 0.688     2.800 
Over 52 1.55 0.026 1.055     2.279 
Sex of study participant 
Male 1   
Female 1.01 0.919 0.798     1.284 
Education level of household head
None 1   
Incomplete 
primary 
1.59 0.011 1.110    2.276 
Primary 1.80 0.0001 1.321     2.464 
O level+ 2.51 0.0001 1.429     4.400 
Socio-economic status 
most poor 1   
very poorer 1.28 0.279 0.821     1.985 
poor 1.48 0.091 0.939     2.320 
Less poor 1.60 0.034 1.038     2.490 
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Least Poor 1.69 0.021 1.083     2.636 
Net use 
No 1   
Yes 1.71 0.001 1.312    2.220 
Religion of household head 
Christianity  1   
Moslem 0.47 0.001 0.358    0 .613 
Local 1.36 0.649 0.361    5.129 
Tribe of household head 
Ndama I   
Pogoro 0.48 0.058 0.224     1.026 
Ngoni 1.62 0.258 0.703     3.713 
Bena 1.91 0.146 0.798      4.544 
Ngindo 0.60 0.181 0.286     1.266 
Hehe 1.28 0.513 0.611     2.674 
Ndengereko 0.41 0.005 0.221     0.765 
Makonde 0.46 0.138 0.164     1.286 
Matumbi 0.83 0.637 0.384     1.797 
unknown 0.75 0.409 0.383     1.478 
District 
Rufiji 1   
Kilombero 0.33 0.0001   0.245    0.450 
Ulanga 0.46 0.0001 0.309    0.700 
Distance of a household to the nearest health facility 
1km 1.26 0.072 0.979    1.631 
5km 1.06 0.637 0.821    1.380 
10km 1.04   0.602 0.901    1.196 
 
 
 
3.4. Multivariate analysis. 
 
The results of the multivariate analysis are summarized in table 3.4 below. After adjusting 
for age group, sex, socio-economic status, educational level of household head, religion of 
household head, the tribe of household head, and the district of the participant, only the age 
group, educational level of the household head, and the district location remained 
statistically significant in the final multivariate model. In the model, participants who were 
between 23 and 28 years old were 2.18 times more likely to obtain treatment than the 
under five years old, [adjusted OR = 2.18, P-value= 0.005, (95% CI: 1.260, 3.774)]. 
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Participants aged between 35 and 40 years were also 2.24 times more likely to obtain 
treatment than the under five year age group, [adjusted OR=2.24, P-value=0.002, (95% CI: 
1.347, 3.729)] while participants above 52 years were  2.36 times more likely to obtain 
treatment, [adjusted OR=2.36,P-value =0.001, (95% CI:1.529, 3.631)].The difference 
between the other age groups and the comparison age group; the under fives were not 
statistically significant. 
 
Participants whose household heads had education up to Ordinary level or beyond the 
ordinary level were 1.94 times more likely to obtain treatment than participants whose 
household heads had never been to school. [Adjusted OR= 1.94, P-value=0.036, (95% CI: 
1.044, 3.588)]. 
 
The multivariate analysis also showed that participants from the Kilombero/ Ulanga 
districts were less likely to obtain treatment compared to those from the Rufiji district. 
Those from the Kilombero district were 0.5 (50%) times less likely to seek treatment 
compared to those from Rufiji district, which had a comparison odds of 1, [adjusted 
OR=0.5, P-value=0.026, (95% CI: 0.268, 0.918)], while those from the Ulanga district 
were 0.67 (67%) times less likely to obtain treatment compared to those from Rufiji 
district, but this is not statistically significant after adjusting for all possible confounding 
factors. 
 
Socio-economic status, tribe of the household head, religion of the house head and bed net 
use were not found, on the multivariate analysis, to be statistically associated with 
obtaining treatment for malaria/fever. Also the multivariate analysis showed that distance 
to a health facility is not a predictor of treatment. Participants who lived within a kilometre 
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away from the nearest health facility were 1.25 times more likely to obtain treatment than 
those whose households were far more than 1km away from the nearest health facility but 
this was not statistically significant after adjustments for possible confounders, [adjusted 
OR=1.25, P-value=0.169, (95% CI:0 .910, 1.710)],. Participants whose households were 
within 5 kilometres from the nearest health facility were less likely to seek 
treatment,[adjusted OR=0.94, P-value=0.708, (95% CI: 0.693, 1.283)] while those who 
lived within 10 kilometres from a health facility were 1.08 times more likely to obtain 
treatment compared to those living beyond 10 kilometres from a health facility, but these 
findings were  not statistically significant. [OR=1.08, P-value=0.331 (95% CI: 0.930146, 
1.256], after adjustments for possible confounders. 
 
Table3.4: Odd Ratios together with 95% confidence intervals for multivariate analysis 
examining the association between treatments of reported malaria and explanatory 
variables. 
 
Variable 
OR P-value 95% CI 
Age group 
Under fives 1   
5-10 1.18 0.404 0.798,    1.750 
11-16 1.13 0.700 0.597,    2.157 
17-22 1.67 0.071 0.957,    2.909 
23-28 2.18 0.005 1.260,    3.774 
29-34 1.45 0.176 0.842,    2.55 
35-40 2.24 0.002 1.347,    3.729 
41-46 1.45 0.268 0.753,    2.776 
47-52 1.61 0.224 0.748,    3.460 
Over 52 2.36 0.001 1.529,    3.631 
Sex of study participant 
Male 1   
Female 0.987938 0.927 0.761,    1.283 
Education level of household head
None 1   
Incomplete primary 1.18 0.427 0.786,    1.764 
Primary 1.36 0.098 0.944,    1.970 
O level+ 1.94 0.036 1.044,     3.588 
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Socio-economic status 
 Poorest 1   
Poorer 1.28 0.315 0.791,    2.071 
Pro-poor 1.43 0.147 0.880,    2.342 
poor 1.54 0.081 0.949,    2.506 
Least Poor 1.42 0.194 0.835,    2.432 
Net use 
No 1   
Yes 1.07 0.719 0.748,    1.523 
Religion of household head 
Christianity 1   
Moslem 0.74 0.237 0.447,    1.220 
Local 2.65 0.214 0.570,   12.339 
Tribe of household head 
Ndama 1   
Pogoro 0.71 0.430 0.305,   1.660 
Ngoni 2.25 0.081 0.905,    5.588 
Bena 1.94 0.149 0.787,    4.795 
Ngindo 1.13 0.790 0.466,    2.731 
Hehe 1.22 0.610 0.571,    2.594 
Ndengereko 1.01 0.981 0.431,    2.369 
Makonde 0.96 0.942 0.296,    3.094 
Matumbi 2.03 0.129 0.814,    5.065 
55 0.79 0.510 0.388,     1.602 
District 
Rufiji 1   
Kilombero 0.50 0.026 0.268,    0.918 
Ulanga 0.67 0.129 0.400,    1.124 
Distance of a house hold to the nearest health facility
Not within 1   
Within 1km 1.25 0.169 0.910,    1.710 
Not within 1   
within5km 0.94 0.708 0.693,      1.283 
Not within 1   
within10km 1.08 0.331 0.926,      1.256 
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CHAPTER FOUR 
4.0   DISCUSSION 
 
This study intended to examine the association between access to antimalarials for 
treatment of reported malaria/fever and household level variables, distance to health 
facilities and demographic variables in the Kilombero/Ulanga and Rufiji valleys, areas that 
cut across three districts in Tanzania. 
 
In the primary study of the household survey, an overall 11.6% (1433/12381) of the total 
number of respondents reported experiencing malaria/fever in the two weeks recall period 
preceding the interview. This figure, 11.6%, representing prevalence of malaria/fever in 
the study areas in 2005 may represent an underestimation or over estimation as the 
specificity of the case definition of malaria in this study could not be ascertained. A study 
by Patrick Kachur etal, in 2004 on prevalence of malaria among clients seeking treatment 
for fever or malaria at drugs store in rural Tanzania showed that 24% of the people who 
experienced fever and reported to drugs stores to purchase antimalarials were actually 
diagnosed with malaria even though 10.7% of them had reported before that they had 
malaria/fever23.Some of the reported fever could be due to either upper respiratory 
infections, thereby inflating the prevalence of malaria/fever during this study. On the other 
hand, it is possible those who reported that they did not experience malaria/fever might 
actually had malaria for the simple reason that they could not recognise it or might have 
forgotten that they had experienced one some few days back. 
 
Some people, especially in rural communities, have different perceptions and 
understanding of malaria or fever. While some may recognise fever as a sign of possible 
malaria infection, others may not recognise the symptoms of malaria and may attribute 
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fever to some causes. Malaria is perceived in the Dangbe community in Ghana as a disease 
caused by excessive contact with external heat which upsets the blood equilibrium24 . 
 
A cross- sectional survey in the Kibaha district in Tanzania on care-givers perceptions of 
clinical manifestations of childhood malaria in holo-endemic rural communities in 
Tanzania revealed that only 15.7% (68/432) of the care givers, presenting their children 
with severe malaria attacks mentioned convulsion as symptoms of severe malaria.25 
However, there is evidence of correlation between traditional symptoms and laboratory 
confirmation of malaria.26 Thus, figures reported by different studies on self reporting of 
malaria vary from one setting to another depending on a variety of factors including local 
believes and altitudes towards the symptoms of the disease. 
 
Analysis in this study has revealed that 32% of all those who had reported malaria/fever 
obtained treatment with any antimalarial. The analysis also revealed that treatment of self 
reported malaria/fever with antimalarials increased across age groups. 
 
Studies on treatment of malaria/fever with antimalarials have found mixed results in many 
African countries. A community based cross- sectional survey in the Tulu District in 
southern –central Ethiopia in 2003, found treatment seeking for malaria to be similar 
across age groups20. The study further revealed that 14% of a total of 12, 225 interviewed 
had reported malaria within a two weeks recall period preceding the interview. Out of 
those who reported malaria, 13% reported seeking treatment within 24 hours of the onset 
of fever20. Another household survey in  Togo  revealed that 20% (95% CI: 20%-27%) of 
under five children obtained treatment with antimalarials obtained from a health centre 
 37 
 
 
while 83% of the remaining children interviewed obtained treatment at home with an 
antimalarial21. 
 
According to the Africa malaria report, 2003, surveys in nineteen African countries 
revealed that half of the febrile children living in malaria endemic countries seek treatment. 
The same Africa malaria report, 2003, also states that surveys in twenty eight African 
countries showed that treatment of fever in children less than five years of age is about 
42%, though source of care seeking differs from place to place, and that more than 80% of 
the respondents used Chloroquine.  
 
  The findings of this study on prevalence of treatment, (32%), and pattern of treatment 
across age groups for the reported malaria/fever in the Rufiji and Kilombero/Ulanga 
valleys differ from the results of the surveys that were carried out in Ethiopia and Togo. 
There is also difference between the findings here and what is presented by the WHO 
Africa malaria report, 2003. Many reasons may account for this .At the time of the surveys 
compiled by the WHO Africa malaria report; many Africa countries were still using 
chloroquine as a first line drug for treatment of uncomplicated malaria. This is supported 
by the Ethiopian survey which reported that 88% of respondents had used chloroquine to 
treat self reported feve20.  
 
By 2001, Tanzania had replaced chloroquine with Sulfadoxine Pyreminthamine (SP) as a 
first line drug for treatment of uncomplicated malaria11. Chloroquine was much more 
affordable than SP and other antimalarials. It may therefore, be suggested  that the wide 
availability and affordability of chloroquine at the time of the surveys reported by WHO 
Africa malaria report, 2003 might have accounted for the higher prevalence of treatment of 
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self diagnosed fever than what is reported in this study. The analysis here may however 
suggest that the replacement of chloroquine with SP by Tanzania might have gained low 
acceptance. However, this finding does not present conclusive evidence to support this 
assertion. 
 
The  higher coverage of treatment for reported malaria/fever in this study compared to the 
one conducted in Togo maybe due to the fact that this study was carried out in areas served 
by demographic surveillance systems where a lot of research activities are taking place 
including malaria programmes .For example, during this study in 2005, there was a 
piloting programme on combination therapy using Sulfadoxine Pyreminthamine, SP and 
Artesunate,( SP+Art) in a clinical facility in the Rufiji district. Intermittent Preventive 
Treatment of Pregnant women, (IPTP) using SP, is also encouraged in the two demographic 
surveillance areas. These programmes might have accounted for the slightly higher 
coverage of treatment for the disease. There was however, limited information on the 
dataset used for this report to allow for adjustment of the effect of those intervention 
studies on this study. It was not possible to know from the dataset the number of study 
participants who were also enrolled either in the SP+Art combination therapy piloting 
programme or the intermittent preventive treatment for pregnant women in the Rufiji area. 
 
A significant finding in this report is the inverse relationship between age and treatment of 
malaria/fever. The under fives have the greatest burden of malaria, yet receive less 
treatment compared to those above five years of age. This revelation has significance for 
public health intervention programmes to achieve national malaria treatment targets. One 
would expect the age group with the greatest burden of malaria (under fives) to receive 
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more attention .However; this is not the case in the Kilombero/Ulanga and Rufiji areas as 
revealed by this study. 
 
Twenty seven percent, (27%) of the under fives obtained treatment with antimalarials. This 
certainly does not present a good situation for treatment of malaria/fever in the Rufiji and 
Kilombero/Ulanga valleys in Tanzania. Coverage of treatment is low compared to what is 
reported by the WHO on treatment of febrile children less than five years of age in many 
Africa countries.  
 
Some factors such as perceptions and altitudes have been identified to influence care 
seeking for under five children. A study by Peter O Ogunjuyigbe, 2004 title: “Under- five 
mortality in Nigeria: Perceptions and altitudes of the Yorubas towards the Existence of 
‘’Abiku’’ “, established that a lot of people in the study area did not have a clear perception 
of illness and treatment for children. The study further found out that some people attached 
under-five deaths to “Abiku” spirit.27.Another study by Alister C. Munthali in Malawi, 
2005, revealed that treatment of malaria for under fives were delayed due to poor 
perceptions about the aetiology, treatment and prevention of malaria28.In the light of this it 
may be argued that issues of perception and altitudes towards care seeking for under five 
children may partly account for the low level of treatment for under five children in the 
Kilombero Ulanga and Rufiji valleys. 
 
 The mismatched between treatment and age group presents a worrisome picture as those 
who are mostly affected (under fives) are not the ones who seek treatment most for 
malaria/fever. Several reasons may account for this in the Rufiji and Kilombero/Ulanaga 
valleys. A possibility exists that the 23 to 28 years groups and the 35 to 40 years groups in 
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the Rufiji and Kilombero/Ulanga valleys were seeking treatment for fever due to other 
diseases such as upper respiratory infections rather than for malaria. The same reasoning 
could be extended to those aged above 52 years old category. The intermittent preventive 
treatment of malaria in pregnant women, IPTP programme that was running at the time of 
this study could have also influenced the age pattern of care seeking for malaria in the 
study area. If more pregnant women were taking part in the IPTP programme and were 
sampled for this study that would likely influence the pattern of obtaining treatment of 
malaria/fever with antimalarials across the various age groups as the pregnant women 
would more likely fall between 23 to 28 and 35 to 40 years. However, as stated above, 
limited information was available in the dataset used for this report to allow for stratified 
analysis to determine the effect of pregnant women taking part in the Intermittent 
Preventive Treatment of Malaria (IPTP) with SP on the finding of this report.  
 
The findings of this study that socio-economic status is not associated with treatment of 
malaria/fever is inconsistent with the findings of a study by Kachur et al, 2006 in Tanzania. 
They found treatment of self reported fever to be associated with socio-economic status in 
Ifakara, one of the areas where this study was carried out. 
 
The relationship between socio-economic status and health seeking depends to a large 
extend on the household assets that go into the principal component analysis (PCA model) 
and the variation of those assets from one household to another. Many have sought to add 
household living standards to the PCA models to construct indices for wealth index 
classification. Thus, the different approaches to the PCA analysis could account for 
differences in the relationship between socio-economic status and health seeking for 
treatment of malaria/ever. For examples, if the variations of assets across the quintiles 
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gradients are not much, the differences between the better ranked and the poorly ranked 
socio-economic groups will not be much and therefore, will not reflect on the pattern of 
care seeking. 
 
Education level has been found, in many studies, to be associated with care seeking. A 
study in Ethiopia showed that mother’s health seeking behaviours for ill babies improve 
with increase in mother’s educational level and improved socio-economic status of the 
mother/caregiver29. The findings of this study are therefore, consistent with what have been 
known in other areas about the relationship between educational level and care seeking. 
 
It is quite reasonable to understand that participants from the Rufiji district were more 
likely to obtain treatment for malaria/fever than participants from the Kilombero/ Ulanga 
districts as the impact of the combination therapy piloting programme, that was going on in 
the Rufiji district at the time of this survey on the findings of this report cannot be ruled 
out. As stated above, adequate information did not exist to quantify this effect. However, 
one cannot rule out the role of the differences between Rufiji and Kilombero/Ulanga 
districts in terms of health facilities. Rufiji is relatively endowed than the Kilombero/ 
Ulanga districts in terms of health facilities. More health facilities in the Rufiji district 
might have accounted for more of the study participants obtaining treatment there than 
those from Kilombero/ Ulanga districts.  
 
From the multivariate analysis, distance of a household to the nearest health facility could 
not predict treatment of the reported fever/malaria in the Kilombero/Ulanga and Rufiji 
valleys. Literature on the influence of distance of households to health facilities on 
treatment of malaria/fever is scanty. However, some studies have found household distance 
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to health facilities to be a determining factor in health care seeking. For example, a study in 
Malawi by Lawrence Kazembe, Immo Kleinsmchidt and Brian L Sharp, 2006 established 
malaria case fatalities to be related to distance of participants place of residence to health 
facilities. The study showed that areas far from health facilities were associated with 
increased risk of mortality while areas closer to health facilities were associated with 
reduced risk of mortality30. 
 
 Another study in Kenya by Peter W.Gething etal, 2004 also found out that utilization of 
health facilities decreased slightly with increasing distance of participants’ place of 
residence to health facilities up to 6 kilometres31. 
 
However, Mathew Jewett, 200132 on “malaria expenditure analysis: A Case Study of 
Tanzania,” reported that 95% of Tanzanian population live within 5km of a health facility. 
This indicates that there is fair equitable distribution of health facilities in Tanzania. If a 
large segment of the study participants are living within the same or almost the same 
distance from health facilities, it is logical to suggest that this may produce a levelling 
effect and may not be a predictive factor in terms of who obtains treatment for 
malaria/fever. 
 
4.1 Limitations of the study. 
The study was based on both self reported and medically diagnosed episodes of malaria 
experienced in the previous two weeks prior to the interview. There was no way of 
verifying whether respondents correctly reported their malaria experiences in the reference 
period .i.e. the case specific definition of malaria could not be ascertained in this study. 
However, the routine DSS activities collect information on use of Sulfadoxine 
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Pyreminthamine/Fansidar for treatment of malaria during census rounds. The data for this 
study was also collected by the same fieldworkers who had been collecting the DSS data. 
Therefore, the data used for this report is much more accurate than similar studies carried 
out in areas without routine data collection activities. 
 
This is secondary data analysis. Therefore, options were limited in the design and choice of 
variables examined. For example, variables on education level were collected from only 
the household head but not on individual level. This limits the capacity of this study to 
look at how education level influences treatment at individual level. Also factors such as 
who makes the decision and provides the resource for a child to be treated for 
fever/malaria could not be investigated because variables on these were not collected by 
the primary study. Nonetheless, this study provides valuable insights into factors that affect 
treatment of malaria in rural communities. It also provides information that could be used 
to better plan and design similar studies in different settings.  
 
There is recall bias in this report. Participants were asked questions based on a two-week 
recall period. Participants would therefore, not vividly remember whether they actually had 
malaria/fever in the last two weeks preceding the interview. This will certainly affect the 
quality of this report. However, the two week recall period is the reference period used by 
WHO surveys and adopted by many researchers for similar surveys. Therefore, findings in 
this report are of comparable quality. 
 
Variables that were not measured during the survey, for example, education level at the 
individual level would have certainly introduced residual confounding into this study. The 
association between treatment of malaria/fever with antimalarials and the socio-
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demographic variables and distance to health facilities might have been influenced by 
unknown or unmeasured variables such as educational level of the participants. These 
possible confounders which were either unforeseen or could not be measured limits the 
findings of this study. However, the effect of residual confounding would not spuriously 
affect the result of this study. Also it was however, envisaged that a greater number of 
study participants likely to report malaria/fever would be the under five years children. 
Thus, measuring education level of under fives would not make much sense since one does 
not expect under fives to attain any meaningful level of education and more so these under 
fives would not be expected to take or influence decision making on treatment of 
malaria/fever. Measurement errors introduced during the surveys would have also 
introduced residual confounding and this would have affected the result of this study .In 
rural communities many people do not accurately report their age. Incorrect age reporting 
would have also introduced residual confounding. 
 
The inability of the programming language that converted the geo-referenced data into 
distance variables to measure distance as a continuous variables limit the capacity of this 
study to examine or explore the effect of distance as a continuous variable on the use of 
antimalarials for treatment of malaria/fever.  About 35% of the study participants 
households were estimated to be beyond 10km from a health facility. Due to limitations of 
the program, the treatment status of the 35% of the study participants could not be 
determined. This might have confounded the relationship between distance and treatment 
of malaria/fever with antimalarials. 
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CHAPTER 5 
5. CONCLUSION AND RECOMMENDATION 
5.1 Conclusion  
This study has established that treatment of malaria/fever vary according to age and 
educational level of the household head in the Rufiji and Kilombero valleys. The district 
from where the participating individual comes could also predict treatment.  
 
The mismatch between the pattern of malaria/fever across age groups and treatment 
represents a significant finding with far reaching implications for public health policy. It is 
expected that the age group with the greatest burden of malaria/fever would receive more 
attention. This, however, is not the case in this study. This revelation will be important in 
up-scaling of antimalarials including combination therapy policy formulation and 
implementatition in Tanzania and many malaria endemic Africa countries. The finding 
certainly has implications for achieving the millennium development goals of halving 
malaria mortality by 2015 at 1990 levels as more attention needs to be focused on the 
under five children to make any meaningful reduction on malaria mortality. But more 
studies need to be carried to establish if this is the trend in the Kilombero/Ulanga and 
Rufiji area or an isolated finding. 
 
It must also be stated that the illiterate populations as well as the under fives age bracket 
especially in rural Africa communities will have to be targeted in malaria treatment and 
preventive programmes to reduce the continent’s malaria burden, a move crucial to the 
achievement of two key millennium development goals: 1) reduce by two thirds the 
mortality rate of under five children by 2015 and 2) halt and begin to reverse the incidence 
of malaria by 2015. 
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5.2 Recommendations  
It is recommended that consideration is given to the findings of this study for any plan for 
the up-scaling of combination therapy or any malaria treatment programme in the 
communities surrounded by Kilombero/Ulanga and Rufiji valleys. However, further 
research needs to be carried out to validate these findings as many factors are known to 
affect treatment of malaria/fever. For example, it may be more useful to consider 
community perceptions and altitudes towards malaria diagnosis and treatment. Integrating 
a qualitative approach into quantitative models will present a holistic and probably a 
clearer picture on how rural communities recognise and seek treatment for malaria with 
antimalarials. This will be crucial for malaria treatment policies.  
 
The impact of direct cost of antimalarials on access to antimalarials for treatment of 
malaria/fever will have to be considered in multinomial models in future research so that a 
greater picture of factors that affect treatment of malaria/fever can be presented. 
Households may have certain assets which are not immediately accessible to meet pressing 
health needs. Therefore, household assets meant for creation of wealth index will have to 
be carefully chosen. Family income and other assets which are more likely to be used to 
meet pressing needs will have to be considered for PCA analysis rather than household 
characteristics which are likely not to reflect on how a household meets medical expenses. 
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Appendix 1:  Map of Tanzania showing the study area ( in red), the Rufiji and Kilombero 
valleys 
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 Appendix 2: Human Research Ethics clearance Certificate from Wits 
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Fourth Cross Section HH survey Kilombero, Ulanga and Rufiji Districts 
CDC/IHRDC Malaria Programme in Tanzania  
 
Module B 
 
Member Section 
 
Fill one form for every member within household  
 
District Initials         |____|   
 
Village Initials        |___|___|___|   
 
Household Number       |___|___|___|___|___| 
 
Date of Interview      |___|___|/|___||___|/|___|___| 
 
Name of the Person ________________________   
 
Sex  1=Male 2= Female       |____|    
 
Date of Birth        |___|___|/|___|___|/|___|___|    
 
Ask the following questions for every adult member. If the member is under 12 the 
respondent should be the parent/Guardian living with the child  
 
23:- What is your relationship with the above mentioned person 
1= Myself (this person must be more than 11 years of age)                    |____| 
2=Mother 
3=Father 
4=Grand mother 
5=Grand father 
6=Uncle/Aunt 
7=Brother/Sisters 
8=Other/Explain        ________________________________________ 
 
24:- Did you/(child) sleep under net last night? 
 
1= Yes    2= No     9= Don’t now                |____| 
If know skip to question 25 
 
24_1 when was the net purchased    |___|___| / |___|___|___|___| 
“99/9999”                  Month / Year 
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24_2 Have you ever treated your net ? 
 
1= Yes    2= No     9= Don’t know                 |____| 
If know skip to question 25 
 
24_3 When was the last time your net was treated? 
 
        |__|__| / |___|___|___|___| 
If don’t know write “99/9999”          Month / Year 
25:- Within the last 4 months did you (child) get blisters all over your (his/her) body.  
 
1= Yes    2= No     9= Don’t know                 |___| 
 
If no or don’t know skip to question 26 
 
25: a: Did you /(child) visit any dispensary /health centre/hospital for treatment of 
this disease? 
1= Yes    2= No     9= Don’t know               |___| 
 
25: b: Describe name place where you visited first 
 Name   |__|___|___|___|___|___|___|___|___|___|___|___|___|___| 
Village |___|___|___| other place|___|___|___|___|___|___|___|___| 
If it’s within Dss area fill Initials: Out Dss area Fill in the name of the village or town 
 
26 Have you ever failed to walk properly or not be able to speak perfectly within the last 4 
moths?  
1= Yes    2= No     9= Don’t know                 |___| 
If no or doesn’t know skip to question 27 
 
26: a: Did you /(child) visit any dispensary /health centre/hospital for treatment of 
this disease? 
1= Yes    2= No     9= Don’t know                 |___| 
If no or don’t know skip to question 27 
 
26: b: Describe name place when you visited first 
 Name   |__|___|___|___|___|___|___|___|___|___|___|___|___|___| 
Village |___|___|___| other place|___|___|___|___|___|___|___|___| 
If it’s within Dss area fills Initials: Out Dss area Fill village or town 
 
27:- Did you /(child) had fever or malaria within the last 14 Days 
1= Yes    2= No     9= Don’t know                 |___| 
If no or doesn’t know skip to the end of the questionnaire 
 
28:- When did this disease start (how many days have passed)? 
00=Today      01 to 86 = Number of days 87= More than 86 99= Don’t know  |___|___| 
 
 
29:- Do you/(child) feel sick today? 
1= Yes  2= No   9= Don’t know        |___| 
If no or doesn’t know skip to question 31 
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30 If yes, for how long /(child) have you been suffering from this disease? 
00=Today      01 to 86 = Number of days 87= More than 86 99= Don’t know   |___| 
 
31:- What were the symptoms? (Don’t read from the list) 
 1=mentioned     2= not mentioned 
 
|__| Fever, Body temperature   |__| Cold/shivering 
|__| Headache     |__| Body pain 
|__| Dizziness     |__| Diarrhea 
|__| Vomiting     |__|Coughing 
|__| Fast breathing    |__|Loss of consciousness  
|__|Convulsion 
|__|Other/Describe _____________________________________________ 
|__| don’t know 
 
32: Have you/(child) received any treatment for this disease? 
1= Yes  2= No   9= Don’t know   |___| 
 
 
32-a If the answer is yes, where did you receive this treatment in the first place?  
|__|__|__|__|__|__|__|__|__|__|__|__|__|__| 
 
After that, did you receive any treatment from any other place/person?  
 
33. Keep on asking questions till all the places of medical care are answered.  Fill 1 in the box 
for the first place 2 for the second place if it’s used etc. If the place of medical care the patient 
did not attend fill 0 
 
Explain to her/him all places of medical care that he/she did not describe. If the place of 
medical care was used more than once fill into another box 
 
1- Hospital                                                       |__| |__| |__| =>Module C 
2- Health centre                                               |__| |__| |__| =>Module C 
3- Normal Shop |__| |__| |__|=> Module C  
4- Pharmacy |__| |__| |__|=>Module C 
5- Village health workers |__| |__| |__|=> Module C 
6- Traditional healers |__| |__| |__|=> Module C 
7- Private lab |__| |__| |__|=> Module C 
8- Other medical care giver |__| |__| |__|=> Module C 
9- Natural herbs |__| |__| |__|=> Module C 
10- Home first aid kit  |__| |__| |__| 
11- Home first aid kit from the neighbor  |__| |__| |__| 
(Not a member of the family) 
 
 
If she/he mentioned 10 / 11 within question no 32a (Home, relative, Neighbour) ask 
question no 33 otherwise skip to question 34 
 
 
 59 
 
 
                                                                                                                                                    
33a Drugs 
If he/she mentioned 
generic name try to 
ask name used in 
business  
33b Amount which 
you received 
1=Tablets 
2=Bottle 
3=Injection 
4=Tube 
5=Packet (ORS) 
9=Don’t know 
33c When did you 
get this medicine? 
(past several days) 
00=Today 
1-86 Number of days 
87=More than 86 
days 
99= Don’t know
33d Where did you 
get this medicine? 
1=Home 
2=Relative/next door 
neighbor 
3=Other 
9=Don’t know 
33e How much did 
you pay for this 
medicine? 
77777=Free or from 
home stock 
99999= Don’t know 
|__|___|__|__|_| Mark      |___| 
|__|__|.|___| 
 |___|___| 
days past 
     |____| |__|__|__|__|__| 
|__|__|__|__|__| Mark      |___| 
|__|__|.|___| 
 |___|___| 
days past 
     |____| |__|__|__|__|__| 
|__|__|__|__|__| Mark      |___| 
|__|__|.|___| 
 |___|___| 
days past 
     |____| |__|__|__|__|__| 
|__|__|__|__|__| Mark      |___| 
|__|__|.|___| 
 |___|___| 
days past 
     |____| |__|__|__|__|__| 
|__|__|__|__|__| Mark    |___| 
|__|__|.|___| 
 |___|___| 
days past 
     |____| |__|__|__|__|__| 
33f. if he/she doesn’t know the price of each medicine write exact total              Tsh  |__|__|__|__|__| 
 
 
 
34:- Is it necessary to fill module C?        |__| 
1= Yes    2= No      
If no or don’t know skip to question 36 
 
35:- If yes, how many module C do you have to fill?     |__| 
If the member is a female aged 15 and above finish question 36 -44 if the answer is no skip 
to the end of the questionnaire 
 
36:-Have you been pregnant for the past 2 year’s?     |__| 
1= Yes  2= No   9= Don’t know    
If the answer is no or does not know skip to the end of questionnaire 
 
The following questions concern your last pregnancy for the past 2 years. 
 
37:- During your pregnancy did you attend  ANC clinic for check up? 
1= Yes    2= No     9= Don’t know                 |____| 
If no or doesn’t know skip to the end of questionnaire 
 
38:- What was the age of the pregnancy when you started attending ANC clinic for 
the first time? 
        99= Don’t know    Weeks|____|____| 
 
 
39:- How many times did you attend clinic for check up before giving birth?  
        99= Don’t know       |____|____| 
  
40:- Did you use Fansidar/Sp to prevent malaria during your pregnancy? 
1= Yes  2= No   9= Don’t know                                                  |___| 
If the answer is no skip to question 41  
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40:a  How many times did you use those drugs? 
1= Yes  2= No   9= Don’t know                                                         |___| 
 
40: b How many pills did you take for a dose? 
 
1= Yes  2= No   9= Don’t know               |___| 
 
40: c Where did you receive these treatments? 
 
Name |__|___|___|___|___|___|___|___|___|___|___|___|___|___| 
Village |__|___|___| other place|___|___|___|___|___|___|___|___| 
If it’s within Dss area fill Initials: Out of the Dss area Fill village or town 
 
41 Can I see your ANC Clinic Card for your latest pregnancy?  
 
1= Yes  2= No            |____| 
 
If the answer to the question its no or doesn’t know skip to end of the questionnaire  
 
 In case you get the ANC Card complete the questions according to card 
  
42 How many weeks was the mother pregnant when she visited ANC clinic for the 
first time? 
 
01 to 40 = Write exact number of weeks  Week |____|____| 
 
43 How many times did the mother pay visit to the clinic before she gave birth? 
 
        |____|____| 
 
44 How many times did she use Sp during her pregnancy? 
 99= Don’t know        |____|____| 
 
 
44: a  How many pills she swallowed at once 
 01 to 09 = Write Exactly number              9= Don’t know       |____| 
 
Thank you for your cooperation do you have any questions or comment 
              
   |___|___| Interviewer                Checked by |____|____| 
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Fourth Cross-Sectional HH Survey Kilombero, Ulanga and Rufiji Districts 
CDC/IHRDC Malaria Programme in Tanzania 
 
 
Module C: 
 
District       _________________________________ 
 
Village Initials            |____|____|____| 
      
Household Number        |____|____|____|____| 
 
Date of Interview      |____|____|/|____|____|/|____|____| 
       
Name of Person     ________________________________ 
              
Person Number                   |____|____| 
     
Sex    1=Male 2= Female             |____| 
  
Date of birth      |____|____|/|____|____|/|____|____|  
  
 
45. Name of the Place of Medical Care      __________________________  
 
Village       ___________________________ 
 
46. Place type 
 
1= Government Hospital/Health Centre/ Dispensary        |____| 
2= Non Government Hospital/Health Centre/ Dispensary 
3=Pharmacy 
4=Village health worker 
5=Normal shops 
6= Village Nurse 
7=Traditional Healer 
8=Other place, describe _____________________________ 
 
Now I will ask questions about your visit to this place 
 
 47. When did you visit that place? 
 
00  = Today       Days passed  |____|____| 
01-86 = Specific days  
87 = More than 86 Days 
99 = Don’t know 
 
If the place is a shop skip to question 48 
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47-a.  Patient was admitted? 
 1= Yes         |____| 
 2=No 
 9= Don’t know    
 
If the answer is No, skip to question 48 
 
47-b if yes how many days was the patient admitted                    |____| 
 
00=Less than one day     01-86= Total number of days 87=More than 86 days  
99= Don’t know 
 
48- Who visited the place of Care? 
 
Sick person (Patient)   - 1= Yes 2 = No                             |_____| 
Other Adults – (More than 12 Yrs of Age)           (Total)          |_____| 
Children under 13                                                (Total)      |_____| 
 
49-What kind /Type of Transport was used to reach the place of care? 
 
1=By Foot   2= Bicycle 3= Motorbike   4= Public Transport    |____| 
5 = Other (specify) ___________________        
 
50-How long did it take to reach the place of care? 
 
1= More than 15 minutes       |____| 
2= Between 15 to 1 hour 
3= Between 1 hour to 2 hours      
4= More than 2 hours 
9= Don’t know       
 
51. What is the transport cost to the place of care? 
 
77777= Free 
99999 = Don’t know      Tshs |___|____|____|____|____| 
 
 
 
52-Time Spent receiving medical service at the place of care 
Please include time spent to see the doctor, time spent waiting for medical service, lab 
testing, receiving drugs, and if the patient admitted to the center include time spent up to 
getting the bed. 
1= Less than 15 minutes       |____| 
2= Between 15m to 1 hour 
3= Between 1 hour to 2 hours 
4= More than 2 hours 
9= Don’t know       
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If the place is a shop skip to question 54 
 
53- Did you spend any night outside your home in order to attend the place of care? 
1=Yes    2=No                                                 |____| 
 
53-a. How much did you spend on the place you slept on that night? 
77777=Free 
99999=Don’t know     Tshs |____|____|____|____|____| 
 
54- Did you spend money on food or soft drinks during your visitation at the place of 
care? 
1= Yes          |____| 
2=No 
      
If the answer is “No or Don’t know” skip to question 55 
 
54_a How much did you spend?   
 
77777= Free 
99999= Don’t know              Tshs        |____|____|____|____|___| 
 
55. Type of Transportation used from the place of Care 
 
1=By Foot           |____| 
2= Bicycle  
3= Motorbike    
4= Public Transport  
5= Other Name / Describe    
 
56. Time spent getting back from the place of Care 
 
1 = Less than 15 minutes       |____| 
2 = Fifteen minutes to 1 hour 
3= 1 hour or 2 hours 
4= More than 2 hours 
5=Don’t know     
 
 
58. How much did you spend on transport on your return from the place of care?   
77777= Free       Tshs        |____|____|____|____|___| 
99999= Don’t know  
   
59. Did you receive any medical service (Child received any Medical service) from the 
place of care?  
 
1=Yes             |____| 
2=No     
9= Don’t know  
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59.a Name of the 
Drug 
59. B What amount of drugs did 
you receive? 
 
1=Tablets 
2=Bottle 
3=Injection 
4=Tube 
5=Packet=(ORS) 
9=Don’t know 
59.c Did Nurse/Medical 
officer decide to provide 
you with this medicines 
or it was your own 
decision?  
1=Nurse/Medical officer 
2=Myself 
 
59. d How much did you 
Pay? 
 
Tshs 
|____|____|____|____|___| 
 
77777=Free 
99999=Don’t know 
 Mark |_|.  
|__|___|.|__| 
          |___|  |_|_|_|_|_|_| 
 Mark |_| 
 
|__|___|.|__| 
           |___| |_|_|_|_|_|_| 
 Mark |_| 
 
|__|___|.|__| 
           |___| |_|_|_|_|_|_| 
 Mark |_| 
 
|__|___|.|__| 
            |___| |_|_|_|_|_|_| 
 Mark |_| 
 
|__|___|.|__| 
            |___| |_|_|_|_|_|_| 
 Mark |_| 
 
|__|___|.|__| 
            |___| |_|_|_|_|_|_| 
{59.If he/she does not know the price of each drug fill-in the total price               Tsh         |__|__|__|__|___|___| 
 Now I will ask questions concerning costs of other medical charges 
 
60. How much did you pay for each of the stated services?  
77777= Free 
99999= Don’t know 
 
A: - Registration   Fees/Card    TSH |__|__|__|__|__| 
B: - Consultations Fees    TSH |__|__|__|__|__| 
C: - Syringe      TSH |__|__|__|__|__| 
D: - Lab test Fees     TSH |__|__|__|__|__| 
E: - Incentive/appreciation    TSH |__|__|__|__|__| 
F: -   Other      TSH |__|__|__|__|__| 
G: -   Other       TSH |__|__|__|__|__| 
 
 (If she/she does not know to the price of each service, write the exact total) 
Tshs                |___|___|___|___|___| 
 
    
62:-Did you pay anything instead of cash at this place? 
 
1= Yes         |_____| 
2=No 
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9=Don’t know 
If yes, describe      _______________________________ 
 
63:- Did you receive any kind of treatment through a loan? 
 
1= Yes         |_____| 
2=No 
9=Don’t know 
If yes, describe  _______________________________ 
 
Interview      |_____|_____| 
 
Checked       |_____|_____| 
 
 
 
 
